News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy – Cancer Network
Photo from Cancer Network/X
May 21, 2024, 15:16

A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy – Cancer Network

Cancer Network shared a post on X:

“A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.”

View additional information.
Source: Cancer Network/X

BCMA cancer Cancer Network CAR T-cell therapy multiple myeloma Myeloma OncoDaily Oncology
Special Coverage
Blog
Feb 22, 2025, 04:25
Empower families to face their cancer journey with strength and hope - Cancer Hope Network
Blog
Feb 22, 2025, 04:19
Secure your spot for the CCI4EU Online Course by ESO
Blog
Feb 22, 2025, 04:16
Manchester Cancer Research Centre will continue its leadership in early detection science following the renewal of ACED
Blog
Feb 22, 2025, 04:12
Citrus Oncology is part of the 14 startups selected for the 2025 CancerX Accelerator
Science
Feb 22, 2025, 04:08
Anticancer potential of NO-Donor Oxadiazole in malignant pleural mesothelioma - The Babak Lab
Blog
Feb 22, 2025, 03:56
Early bird registration deadline for the 15th CCI Europe Conference approaches
Blog
Feb 22, 2025, 03:52
Share Your MASCC Guidelines Experience
Insight
Feb 22, 2025, 03:44
George Vlachogiannis: Cutting cancer mortality in Canada by 50% by 2050 - can we get there?
Blog
Feb 22, 2025, 03:21
Brian Kim: Unsolicited advice to new PIs
Blog
Feb 22, 2025, 03:18
Christine Lovly: Why is NIH important?
Blog
Feb 22, 2025, 02:53
Wafaa M Rashed: Empowering Voices in Genetics and Genomics Advocacy with Deborah Ekusai Sebatta
Blog
Feb 22, 2025, 02:50
Danielle Bitterman Calls on Conference Leaders to Provide Hybrid Options for HHS-Funded Scientists